United Therapeutics (UTHR) Share-based Compensation (2009 - 2026)

United Therapeutics has reported Share-based Compensation for 18 years, with the latest figure at $58.3 million in Q1 2026.

• Quarterly Share-based Compensation rose 281.05% year-over-year to $58.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.6 million (up 270.19% YoY) and the FY2025 annual result came in at $16.6 million, up 36.07% from the prior year.
• Share-based Compensation grew to $58.3 million in Q1 2026 per UTHR's latest filing, from -$92.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $105.5 million in Q3 2024 and troughed at -$104.8 million in Q4 2024.
• A 5-year average of $6.6 million and a median of $11.4 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2024: Share-based Compensation slumped 15400.0% in 2022, then surged 400.0% in 2024.
• Over 5 years, Share-based Compensation stood at -$30.6 million in 2022, then surged by 71.57% to -$8.7 million in 2023, then tumbled by 1104.6% to -$104.8 million in 2024, then rose by 12.12% to -$92.1 million in 2025, then surged by 163.3% to $58.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $58.3 million, -$92.1 million, and $93.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.